In this study we therefore set out to assess expression of the target protein Cdc7 in pancreatic cancer (target validation) and to test therapeutic anti-cancer potential by targeting Cdc7 kinase in pancreatic cancer cell line models using both siRNA and the PHA-767491 small molecule inhibitor (SMI) treatment strategies. This evidence concerns the gene CDC7 and familial pancreatic carcinoma.